Prospective trial to evaluate the prognostic value of different nutritional assessment scores in pancreatic surgery (NURIMAS Pancreas). BJS 2017; 104: 1053-1062.
Published: 30th March 2017
Authors: P. Probst, S. Haller, T. Bruckner, A. Ulrich, O. Strobel, T. Hackert et al.
Preoperative nutritional status has an impact on patients' clinical outcome. For pancreatic surgery, however, it is unclear which nutritional assessment scores adequately assess malnutrition associated with postoperative outcome.
Patients scheduled for elective pancreatic surgery at the University of Heidelberg were screened for eligibility. Twelve nutritional assessment scores were calculated before operation, and patients were categorized as either at risk or not at risk for malnutrition by each score. The postoperative course was monitored prospectively by assessors blinded to the nutritional status. The primary endpoint was major complications evaluated for each score in a multivariable analysis corrected for known risk factors in pancreatic surgery.
Overall, 279 patients were analysed. A major complication occurred in 61 patients (21·9 per cent). The proportion of malnourished patients differed greatly among the scores, from 1·1 per cent (Nutritional Risk Index) to 79·6 per cent (Nutritional Risk Classification). In the multivariable analysis, only raised amylase level in drainage fluid on postoperative day 1 (odds ratio (
None of the nutritional assessment scores defined malnutrition relevant to complications after pancreatic surgery and these scores may thus be abandoned.Read more
You may also be interested in
Authors: R. Ahola, A. Siiki, K. Vasama, M. Vornanen, J. Sand, J. Laukkarinen et al.
Notes: Centralization influences long‐term survival
Systematic review of transarterial embolization for hepatocellular adenomas. BJS 2017; 104: 823-835.
Authors: B. V. van Rosmalen, R. J. S. Coelen, M. Bieze, O. M. van Delden, J. Verheij, C. H. C. Dejong et al.
Notes: Safe alternative to surgery
Meta‐analysis of adjuvant therapy following curative surgery for periampullary adenocarcinoma. BJS 2017; 104: 814-822.
Authors: A. Acharya, S. R. Markar, M. H. Sodergren, G. Malietzis, A. Darzi, T. Athanasiou et al.
Notes: No benefit
Authors: T. Ebata, T. Mizuno, Y. Yokoyama, T. Igami, G. Sugawara, M. Nagino et al.
Notes: irresectability revisited
Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma. BJS 2017; 104: 1045-1052.
Authors: H. Kim, S. W. Ahn, S. K. Hong, K. C. Yoon, H.‐S. Kim, Y. R. Choi et al.
Notes: Selected patients benefit
Accuracy of circulating histones in predicting persistent organ failure and mortality in patients with acute pancreatitis.
Authors: T. Liu, W. Huang, P. Szatmary, S. T. Abrams, Y. Alhamdi, Z. Lin et al.
Notes: Potential as early prediction biomarker
Dual hypothermic oxygenated machine perfusion in liver transplants donated after circulatory death. BJS 2017; 104: 907-917.
Authors: R. van Rijn, N. Karimian, A. P. M. Matton, L. C. Burlage, A. C. Westerkamp, A. P. van den Berg et al.
Notes: Increases donor pool
Authors: F. J. Hüttner, P. Probst, P. Knebel, O. Strobel, T. Hackert, A. Ulrich et al.
Notes: No benefit
Prognostic impact of margin status in liver resections for colorectal metastases after bevacizumab. BJS 2017; 104: 926-935.
Authors: K. Sasaki, G. A. Margonis, N. Andreatos, A. Wilson, M. Weiss, C. Wolfgang et al.
Notes: Antiangiogenesis antibody of benefit
Impact of hepatobiliary service centralization on treatment and outcomes in patients with colorectal cancer and liver metastases. BJS 2017; 104: 918-925.
Authors: A. E. Vallance, J. vanderMeulen, A. Kuryba, I. D. Botterill, J. Hill, D. G. Jayne et al.
Notes: Better survival
Liver transection using indocyanine green fluorescence imaging and hepatic vein clamping. BJS 2017; 104: 898-906.
Authors: Y. Kawaguchi, Y. Nomura, M. Nagai, D. Koike, Y. Sakuraoka, T. Ishida et al.
Notes: To see or not to see
Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status. BJS 2017; 104: 760-768.
Authors: B. C. Odisio, S. Yamashita, S. Y. Huang, S. Harmoush, S. E. Kopetz, K. Ahrar et al.
Notes: Mutant RAS poor prognostic factor